Abbott India , a leading healthcare company, has announced the launch of its latest innovation in diabetes management - the FreeStyle Libre 2 Plus. This next-generation glucose monitoring device represents a significant advancement in continuous glucose monitoring technology, offering enhanced features to improve the lives of people managing diabetes.

Cutting-Edge Technology for Minute-by-Minute Monitoring

The FreeStyle Libre 2 Plus sets itself apart with its ability to provide continuous glucose readings every minute. This high-frequency monitoring allows users to track their glucose levels with unprecedented precision, enabling more informed decision-making about their diabetes management.

Advanced Alarm Features for User Safety

One of the standout features of the FreeStyle Libre 2 Plus is its optional alarm system. These alarms can be customized to alert users when their glucose levels fall outside of their target range, providing an extra layer of safety and peace of mind for individuals managing diabetes.

Empowering Diabetes Management

By combining minute-by-minute glucose readings with customizable alarms, the FreeStyle Libre 2 Plus aims to empower users with real-time information about their glucose levels. This continuous stream of data can help individuals and their healthcare providers make more informed decisions about insulin dosing, meal planning, and overall diabetes management strategies.

The launch of the FreeStyle Libre 2 Plus underscores Abbott India's commitment to innovation in the field of diabetes care. As the prevalence of diabetes continues to rise globally, technologies like this play a crucial role in improving the quality of life for millions of people living with the condition.

While the company has not disclosed pricing or availability details in the announcement, the introduction of the FreeStyle Libre 2 Plus is expected to be a welcome addition to the diabetes management toolkit in India, potentially benefiting a significant portion of the population affected by diabetes.

Abbott India Limited , a prominent pharmaceutical company, successfully conducted its 81st Annual General Meeting (AGM) on August 13, 2025, through video conferencing. The meeting saw shareholders approving all proposed resolutions with the required majority, marking a significant milestone for the company.

Key Resolutions Approved

The shareholders gave their nod to several important resolutions, including:

1. Adoption of Financial Statements: The audited financial statements for the year ended March 2025 were adopted.

2. Dividend Declaration: A final dividend per equity share was declared, although the specific amount was not disclosed in the available information.

3. Director Reappointments: Ms. Alison Davies and Mr. Kaiyomarz Marfatia, who retired by rotation, were reappointed as directors.

4. Appointment of Secretarial Auditors: BNP & Associates were appointed as secretarial auditors for five consecutive financial years.

5. Cost Auditor Remuneration: The remuneration of the cost auditor was ratified.

6. New Managing Director: Mr. Kartik Rajendran was appointed as Director and Managing Director for a period of five years, from June 2025 to June 2030.

Voting Process and Scrutiny

The AGM was conducted with both remote e-voting and e-voting facilities provided through National Securities Depository Limited (NSDL). Mr. Husain Wagh of Khumri Wagh Fatehi & Associates LLP served as the scrutinizer for the voting process, ensuring transparency and accuracy.

Detailed Voting Results

The consolidated scrutinizer's report revealed that all resolutions received overwhelming support from the shareholders. Here's a breakdown of the voting results for key resolutions:

The strong support for all resolutions indicates shareholders' confidence in the company's management and future direction.

Compliance and Disclosure

In compliance with regulatory requirements, Abbott India Limited promptly submitted the voting results and the consolidated scrutinizer's report to the BSE Limited. This adherence to transparency norms underscores the company's commitment to good corporate governance practices.

The successful conclusion of the 81st AGM, with all resolutions passed, positions Abbott India Limited for continued growth and development in the pharmaceutical sector. Shareholders' approval of the new Managing Director's appointment and other key resolutions reflects their trust in the company's strategic decisions and future prospects.